Wells Fargo’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$248K Sell
29,863
-39,348
-57% -$408K ﹤0.01% 4579
2025
Q4
$855K Buy
69,211
+17,107
+33% +$183K ﹤0.01% 4087
2025
Q3
$460K Buy
52,104
+6,413
+14% +$49.9K ﹤0.01% 4367
2025
Q2
$292K Buy
45,691
+34,615
+313% +$198K ﹤0.01% 4522
2025
Q1
$53.8K Buy
11,076
+2,729
+33% +$22.6K ﹤0.01% 5369
2024
Q4
$79.8K Sell
8,347
-11,665
-58% -$107K ﹤0.01% 5321
2024
Q3
$167K Buy
20,012
+16,477
+466% +$150K ﹤0.01% 4696
2024
Q2
$24.1K Sell
3,535
-18,771
-84% -$80.8K ﹤0.01% 5531
2024
Q1
$56.4K Buy
22,306
+2,506
+13% +$5.65K ﹤0.01% 5208
2023
Q4
$47.5K Buy
19,800
+2,430
+14% +$5.71K ﹤0.01% 5294
2023
Q3
$59.1K Sell
17,370
-110,265
-86% -$611K ﹤0.01% 5094
2023
Q2
$938K Buy
127,635
+37,261
+41% +$346K ﹤0.01% 3520
2023
Q1
$936K Buy
90,374
+71,435
+377% +$863K ﹤0.01% 3419
2022
Q4
$224K Buy
18,939
+8,252
+77% +$128K ﹤0.01% 4114
2022
Q3
$224K Sell
10,687
-164,923
-94% -$4.59M ﹤0.01% 4180
2022
Q2
$5.45M Sell
175,610
-113,540
-39% -$3.88M ﹤0.01% 2035
2022
Q1
$11.9M Sell
289,150
-26,682
-8% -$1.18M ﹤0.01% 1698
2021
Q4
$13.7M Sell
315,832
-101,319
-24% -$4.58M ﹤0.01% 1611
2021
Q3
$20.9M Buy
417,151
+126,093
+43% +$7.64M ﹤0.01% 1633
2021
Q2
$18.3M Sell
291,058
-170,494
-37% -$11M ﹤0.01% 1737
2021
Q1
$42.9M Buy
461,552
+18,255
+4% +$1.87M 0.01% 1131
2020
Q4
$39.7M Sell
443,297
-164,414
-27% -$15.1M 0.01% 1115
2020
Q3
$62.8M Buy
607,711
+140,558
+30% +$15.2M 0.02% 764
2020
Q2
$36.9M Sell
467,153
-2,074
-0.4% -$155K 0.01% 1014
2020
Q1
$27.1M Buy
469,227
+158,422
+51% +$9.13M 0.01% 1081
2019
Q4
$16.8M Sell
310,805
-20,316
-6% -$1.1M ﹤0.01% 1578
2019
Q3
$17.3M Sell
331,121
-13,070
-4% -$609K ﹤0.01% 1531
2019
Q2
$16.6M Buy
344,191
+187,359
+119% +$8.98M ﹤0.01% 1578
2019
Q1
$7.92M Buy
156,832
+10,342
+7% +$610K ﹤0.01% 2121
2018
Q4
$8.69M Sell
146,490
-494
-0.3% -$31.8K ﹤0.01% 1954
2018
Q3
$9.68M Buy
146,984
+9,395
+7% +$548K ﹤0.01% 2095
2018
Q2
$6.95M Sell
137,589
-9,768
-7% -$509K ﹤0.01% 2393
2018
Q1
$7.76M Buy
147,357
+15,052
+11% +$750K ﹤0.01% 2235
2017
Q4
$6.15M Buy
132,305
+41,169
+45% +$1.73M ﹤0.01% 2409
2017
Q3
$3.69M Buy
91,136
+17,324
+23% +$627K ﹤0.01% 2791
2017
Q2
$2.5M Buy
73,812
+242
+0.3% +$7.47K ﹤0.01% 3029
2017
Q1
$2.14M Sell
73,570
-30,777
-29% -$937K ﹤0.01% 3153
2016
Q4
$3.43M Sell
104,347
-146,907
-58% -$4.4M ﹤0.01% 2705
2016
Q3
$7.92M Buy
251,254
+164,359
+189% +$4.78M ﹤0.01% 1927
2016
Q2
$2.44M Buy
86,895
+8,312
+11% +$326K ﹤0.01% 2827
2016
Q1
$2.86M Buy
78,583
+6,610
+9% +$233K ﹤0.01% 2672
2015
Q4
$2.88M Buy
71,973
+15,882
+28% +$554K ﹤0.01% 2719
2015
Q3
$1.6M Buy
56,091
+33,577
+149% +$1.11M ﹤0.01% 3162
2015
Q2
$742K Buy
22,514
+10,121
+82% +$314K ﹤0.01% 3838
2015
Q1
$356K Sell
12,393
-3,589
-22% -$103K ﹤0.01% 4141
2014
Q4
$435K Buy
15,982
+51
+0.3% +$1.22K ﹤0.01% 4023
2014
Q3
$340K Sell
15,931
-1,529
-9% -$35K ﹤0.01% 4105
2014
Q2
$392K Buy
17,460
+2,098
+14% +$48.9K ﹤0.01% 4037
2014
Q1
$388K Buy
15,362
+4
+0% +$101 ﹤0.01% 4012
2013
Q4
$353K Sell
15,358
-96
-0.6% -$2K ﹤0.01% 3974
2013
Q3
$294K Buy
15,454
+4,565
+42% +$81.5K ﹤0.01% 4018
2013
Q2
$157K Buy
+10,889
New +$158K ﹤0.01% 4234

Other funds holding EBS

Wells Fargo's EBS Position: Q1 2026 in Review

Wells Fargo reduced its Emergent Biosolutions (EBS) stake by 57% in Q1 2026, selling an estimated $408K and leaving 29,863 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #4579.

Wells Fargo first reported a position in EBS in Q2 2013 and has held it in 52 quarters since. The position peaked at $62.8M in Q3 2020. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Wells Fargo held 29,863 shares of Emergent Biosolutions worth $248K as of Q1 2026.
  • Wells Fargo sold 39,348 Emergent Biosolutions shares in Q1 2026, an estimated $408K.
  • Emergent Biosolutions made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4579 holding.
  • Wells Fargo first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Emergent Biosolutions position peaked at $62.8M in Q3 2020.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.